Merck

Executive Summary

Merck & Co., Inc. is a global biopharmaceutical leader with a market capitalization of $293.79B and a diversified portfolio spanning oncology, vaccines, and specialty medicines. The company's flagship product, Keytruda (pembrolizumab), remains a cornerstone of immuno-oncology, generating over $20B in annual sales and driving continuous label expansions. Merck's vaccine franchise, including Gardasil and ProQuad, benefits from strong demand and geographic expansion. In 2025, the company strengthened its pipeline through strategic acquisitions and internal R&D, focusing on cardiovascular, immunology, and antimicrobial areas. With a robust balance sheet and a commitment to innovation, Merck is well-positioned to navigate patent cliffs and sustain long-term growth. Looking ahead, Merck's near-term outlook is supported by several late-stage pipeline candidates. The anticipated approval of sotatercept for pulmonary arterial hypertension could address a significant unmet need, while expansions for Keytruda in earlier treatment settings and combination regimens promise to extend its lifecycle. Additionally, the company's COVID-19 antiviral Lagevrio (molnupiravir) continues to contribute to revenue, albeit with declining demand. Merck's disciplined capital allocation, including share buybacks and dividend growth, further reinforces shareholder value. Despite potential headwinds from generic competition and pricing pressures, Merck's diversified base and innovative pipeline underpin a conviction score of 75.

Upcoming Catalysts (preview)

• Q2 2026FDA approval decision for sotatercept in pulmonary arterial hypertension75% success
• Q3 2026Phase 3 data readout for Keytruda in first-line gastric cancer80% success
• Q4 2026Gardasil 9 label expansion for prevention of HPV-related cancers in males aged 27-4590% success